Search Result

Results for "

Amfenac Sodium

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) ATP-binding cassette (ABC) transporters (1) Bacterial (1) COX (7) Endogenous Metabolite (3) Epigenetic Reader Domain (1) Fungal (1) HSP (1) Isotope-Labeled Compounds (3) Prostaglandin Receptor (3) Reference Standards (3)
By Research Areas:	Cancer (4) Endocrinology (3) Infection (1) Inflammation/Immunology (8) Metabolic Disease (1) Neurological Disease (3)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: Sodium Phosphate Cotransporter Sodium Channel Apical Sodium-Dependent Bile Acid Transporter Na+/H+ Exchanger (NHE) SGLT Na+/K+ ATPase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17479A

Amfenac Sodium Hydrate	COX	Inflammation/Immunology
Amfenac Sodium Hydrate is a COX-2 inhibitor.

HY-17479BS

Amfenac-d5 sodium	Isotope-Labeled Compounds	Others
Amfenac-d₅ sodium is deuterated-labeled Amfenac sodium. Amfenac Sodium is an orally active and potent anti-inflammatory compound possessing antipyretic and analgesic properties. Amfenac Sodium can be used for the research of acute and chronic inflammation .

HY-17357

Nepafenac AHR 9434; AL 6515	COX Prostaglandin Receptor Endogenous Metabolite	Neurological Disease Inflammation/Immunology Endocrinology Cancer
Nepafenac (AHR 9434; AL 6515), a nonsteroidal anti-inflammatory agent, is a topically administered COX-2 inhibitor with an IC₅₀ of 0.12 μM. Nepafenac exhibits only weak COX-1 inhibitory activity (IC₅₀ = 64.3 μM). Nepafenac possesses unique prodrug properties, which enable it to rapidly convert into the active metabolite *Amfenac* (HY-17479) in the ocular tissues, thereby achieving high concentrations in the retina and choroid. Nepafenac reduces inflammation and pain by inhibiting the activity of cyclooxygenase (COX) enzymes and thereby decreasing the production of prostaglandin PGE_₂. Nepafenac can delay the metastasis of uveal melanoma (UM) in rabbit eyes. Nepafenac is mainly used for pain management and inflammation control after ophthalmic surgeries .

HY-17357S

Nepafenac-d5 AHR-9434-d₅; AL-6515-d₅	Isotope-Labeled Compounds COX Prostaglandin Receptor Endogenous Metabolite	Neurological Disease Inflammation/Immunology Endocrinology Cancer
Nepafenac-d₅ (AHR-9434-d₅; AL-6515-d₅) is the deuterium labeled Nepafenac (HY-17357). Nepafenac, a nonsteroidal anti-inflammatory agent, is a topically administered COX-2 inhibitor with an IC₅₀ of 0.12 μM. Nepafenac exhibits only weak COX-1 inhibitory activity (IC₅₀ = 64.3 μM). Nepafenac possesses unique prodrug properties, which enable it to rapidly convert into the active metabolite *Amfenac* (HY-17479) in the ocular tissues, thereby achieving high concentrations in the retina and choroid. Nepafenac reduces inflammation and pain by inhibiting the activity of cyclooxygenase (COX) enzymes and thereby decreasing the production of prostaglandin PGE_₂. Nepafenac can delay the metastasis of uveal melanoma (UM) in rabbit eyes. Nepafenac is mainly used for pain management and inflammation control after ophthalmic surgeries.

HY-17479B

Amfenac sodium AHR 5850 Sodium	COX	Inflammation/Immunology
Amfenac sodium (AHR 5850 sodium) is an orally active and potent anti-inflammatory compound possessing antipyretic and analgesic properties. Amfenac sodium can be used for the research of acute and chronic inflammation .

HY-17479AR

Amfenac Sodium Hydrate (Standard)	COX Reference Standards	Inflammation/Immunology
Amfenac (Sodium Hydrate) (Standard) is the analytical standard of Amfenac (Sodium Hydrate). This product is intended for research and analytical applications. Amfenac Sodium Hydrate is a COX-2 inhibitor.

HY-17479S

Amfenac-d5	Isotope-Labeled Compounds	Others
Amfenac-d₅ is the deuterium labeled Amfenac. Amfenac is an orally active and potent anti-inflammatory compound possessing antipyretic and analgesic properties. Amfenac can be used for the research of acute and chronic inflammation .

HY-17479

*Amfenac*	COX	Inflammation/Immunology
Amfenac (AHR 5850) is an orally active and potent anti-inflammatory compound possessing antipyretic and analgesic properties. Amfenac can be used for the research of acute and chronic inflammation .

HY-W010649R

Isoxazole (Standard)	HSP Reference Standards Epigenetic Reader Domain ATP-binding cassette (ABC) transporters Bacterial Fungal Antibiotic	Infection Metabolic Disease Inflammation/Immunology Cancer
Amfenac (Sodium Hydrate) (Standard) is the analytical standard of Amfenac (Sodium Hydrate). This product is intended for research and analytical applications. Amfenac Sodium Hydrate is a COX-2 inhibitor.

HY-17357R

Nepafenac (Standard) AHR 9434 (Standard); AL 6515 (Standard)	Reference Standards COX Prostaglandin Receptor Endogenous Metabolite	Neurological Disease Inflammation/Immunology Endocrinology Cancer
Nepafenac (AHR 9434; AL 6515) (Standard) is the analytical standard of Nepafenac (HY-17357). This product is intended for research and analytical applications. Nepafenac, a nonsteroidal anti-inflammatory agent, is a topically administered COX-2 inhibitor with an IC₅₀ of 0.12 μM. Nepafenac exhibits only weak COX-1 inhibitory activity (IC₅₀ = 64.3 μM). Nepafenac possesses unique prodrug properties, which enable it to rapidly convert into the active metabolite *Amfenac* (HY-17479) in the ocular tissues, thereby achieving high concentrations in the retina and choroid. Nepafenac reduces inflammation and pain by inhibiting the activity of cyclooxygenase (COX) enzymes and thereby decreasing the production of prostaglandin PGE_₂. Nepafenac can delay the metastasis of uveal melanoma (UM) in rabbit eyes. Nepafenac is mainly used for pain management and inflammation control after ophthalmic surgeries.

Cat. No.	Product Name	Chemical Structure

HY-17479BS

Amfenac-d5 sodium
Amfenac-d₅ sodium is deuterated-labeled Amfenac sodium. Amfenac Sodium is an orally active and potent anti-inflammatory compound possessing antipyretic and analgesic properties. Amfenac Sodium can be used for the research of acute and chronic inflammation .

HY-17357S

Nepafenac-d5
Nepafenac-d₅ (AHR-9434-d₅; AL-6515-d₅) is the deuterium labeled Nepafenac (HY-17357). Nepafenac, a nonsteroidal anti-inflammatory agent, is a topically administered COX-2 inhibitor with an IC₅₀ of 0.12 μM. Nepafenac exhibits only weak COX-1 inhibitory activity (IC₅₀ = 64.3 μM). Nepafenac possesses unique prodrug properties, which enable it to rapidly convert into the active metabolite *Amfenac* (HY-17479) in the ocular tissues, thereby achieving high concentrations in the retina and choroid. Nepafenac reduces inflammation and pain by inhibiting the activity of cyclooxygenase (COX) enzymes and thereby decreasing the production of prostaglandin PGE_₂. Nepafenac can delay the metastasis of uveal melanoma (UM) in rabbit eyes. Nepafenac is mainly used for pain management and inflammation control after ophthalmic surgeries.

Nepafenac-d5

Nepafenac-d₅ (AHR-9434-d₅; AL-6515-d₅) is the deuterium labeled Nepafenac (HY-17357). Nepafenac, a nonsteroidal anti-inflammatory agent, is a topically administered COX-2 inhibitor with an IC₅₀ of 0.12 μM. Nepafenac exhibits only weak COX-1 inhibitory activity (IC₅₀ = 64.3 μM). Nepafenac possesses unique prodrug properties, which enable it to rapidly convert into the active metabolite Amfenac (HY-17479) in the ocular tissues, thereby achieving high concentrations in the retina and choroid. Nepafenac reduces inflammation and pain by inhibiting the activity of cyclooxygenase (COX) enzymes and thereby decreasing the production of prostaglandin PGE_₂. Nepafenac can delay the metastasis of uveal melanoma (UM) in rabbit eyes. Nepafenac is mainly used for pain management and inflammation control after ophthalmic surgeries.

HY-17479S

Amfenac-d5
Amfenac-d₅ is the deuterium labeled Amfenac. Amfenac is an orally active and potent anti-inflammatory compound possessing antipyretic and analgesic properties. Amfenac can be used for the research of acute and chronic inflammation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.